The specter of generic competition has consistently loomed above copyright’s iconic drug, Viagra, triggering questions about the outlook of related drug stakes. While early times saw significant profits, the exclusivity lapse has created the way for discounted copies, potentially reducing revenue and creating a real danger for shareholders seekin